Exelixis Inc (NASDAQ:EXEL) continues to demonstrate impressive growth with their CABOMETYX franchise, as evidenced by their recent second-quarter 2025 financial results. CEO Michael Morrissey and EVP of Commercial Patrick Haley expressed confidence in sustaining market share gains for CABOMETYX, with a strong presence in renal cell carcinoma (RCC) and promising prospects in neuroendocrine tumors (NET).
The company reported total revenues of approximately $568 million, with CABOMETYX net product revenues at $518 million. Collaboration revenues, including royalties from partners Ipsen and Takeda, amounted to $48.2 million. GAAP net income was approximately $184.8 million, while non-GAAP net income reached $212.6 million. Exelixis also repurchased $302 million worth of shares, retiring approximately 7.5 million shares. The cabozantinib US business showed robust growth, with revenues increasing by 19% year over year to $520 million.
Read more from finance.yahoo.com